Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Free fatty acid receptor 4 |
| Gene Name | FFAR4 |
| Uniprot | Q5NUL3 (Human); Q7TMA4 (Mouse) |
| Synonym | GT01; PGR4; BMIQ10; GPR120; GPR129; O3FAR1; G-protein coupled receptor 120; G-protein coupled receptor 129; G-protein coupled receptor GT01; G-protein coupled receptor PGR4; omega-3 fatty acid receptor 1 |
| Background | FFAR4, also known as G-protein coupled receptor 120 (GPR120), G-protein coupled receptor 129 (GPR129), G-protein coupled receptor GT01, GT01, G-protein coupled receptor PGR4, PGR4, or Omega-3 fatty acid receptor 1 (O3FAR1), is a 43 kDa protein belongs to the rhodopsin family of G protein-coupled receptors. In humans, it is encoded by the GPR120 gene of the chromosome 10q23.33. FFAR4 is ubiquitously expressed in various tissues and organs, including lungs, colon, small intestine, thymus, brain, liver, taste buds, heart, skeletal muscle, and adipose tissue. Additionally, its expression in heart, skeletal muscle, and adipose tissue is elevated by a high-fat diet (HFD). |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX275 | NativeExtract™ Human FFAR4 Membrane Protein (Full length, Super Nanodisc) | HEK293 cells | Full length | Native Nanodisc |
| MPX3496K | MemDX™ Membrane Protein Human FFAR4 Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| Please for more products or customization | ||||
R*x: Custom FFAR4 variants delivered in 4 weeks. Optimized protocols ensured seamless integration into our SPR workflows.
27/Aug/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
Creative Biolabs offers FFAR4 gene editing services for metabolic dysregulation. Precise genomic modification of FFAR4 (GPR120), a receptor critical for lipid metabolism and anti-inflammatory signaling, has emerged as a transformative strategy. Gene editing systems enable targeted correction of deleterious mutations in FFAR4 exons linked to insulin resistance or obesity. For instance, in murine models of metabolic syndrome, FFAR4 frameshift variants restored omega-3 fatty acid responsiveness and attenuated adipose inflammation. Creative Biolabs' proprietary RNA design platforms optimize specificity, minimizing off-target effects while enhancing on-target editing efficiency. Integration of these tools accelerates preclinical validation pipelines for metabolic disorders.
Creative Biolabs offers AAV-driven FFAR4 overexpression services. Adeno-associated virus (AAV) vectors engineered with liver-specific promoters facilitate localized FFAR4 overexpression, augmenting hepatic insulin sensitivity. Studies in diabetic models demonstrate that AAV8-mediated FFAR4 delivery reduces hepatic steatosis and normalizes glucose homeostasis within 6–8 weeks post-administration. Creative Biolabs' AAV serotype optimization services ensure tissue-selective transgene expression, while rigorous in vivo biodistribution assays guarantee therapeutic precision.
Creative Biolabs offers comprehensive and innovative services to drive the development of FFAR4 cell therapy. Please for more services.
Creative Biolabs offers FFAR4-expressing CAR-T cells development services. Chimeric antigen receptor (CAR)-T cells engineered to co-express FFAR4 exploit the receptor's dual role in immune regulation and metabolic reprogramming. In tumor microenvironments, FFAR4 activation in CAR-T cells enhances their persistence by reducing lactate-induced exhaustion, as evidenced in syngeneic colorectal cancer models. Creative Biolabs' lentiviral transduction protocols enable stable FFAR4 co-expression, while multiparametric flow cytometry validates functional receptor integration. This approach synergizes antitumor cytotoxicity with metabolic resilience, offering a paradigm shift in solid tumor immunotherapy.
Creative Biolabs offers stromal cell reprogramming via FFAR4 agonist delivery services. Mesenchymal stem cells (MSCs) primed with FFAR4 agonists exhibit enhanced anti-fibrotic and pro-regenerative activity. In rodent models of non-alcoholic steatohepatitis (NASH), FFAR4-activated MSCs reduced collagen deposition by 40% via suppression of TGF-β pathways. Creative Biolabs' 3D co-culture platforms replicate fibrotic microenvironments to quantify MSC efficacy, while RNA sequencing identifies FFAR4-driven transcriptomic signatures. Partner with our team to optimize agonist dosing, delivery matrices, or mechanistic validation for regenerative applications.
Leverage Creative Biolabs' end-to-end cell engineering, functional assays, and translational models to refine FFAR4-centric therapies. to explore scalable solutions for metabolic, inflammatory, or oncologic indications.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
